James Lenehan - Medtronic PLC Independent Director

MDT Stock  USD 86.27  0.59  0.69%   

Director

Mr. James T. Lenehan is Independent Director of the Company. Mr. Lenehan served as President of Johnson Johnson, an international pharmaceutical company, from 2002 until 2004, when he retired after 28 years of service to Johnson Johnson. During those 28 years, Mr. Lenehan also served as Vice Chairman of Johnson Johnson from 2000 until 2004 Worldwide Chairman of Johnson Johnsons Medical Devices and Diagnostics Group from 1999 until he became Vice Chairman of the Board and Worldwide Chairman, Consumer Pharmaceuticals Professional Group. Mr. Lenehan was a financial consultant since 2004, including serving as Senior Advisor of Cerberus Operations and Advisory Company, LLC, a private investment firm. Mr. Lenehan is a former director of Talecris Biotherapeutics Holding Corporationration since 2007.
Age 71
Tenure 17 years
Address Building Two, Galway, Ireland
Phone353 1 438 1700
Webhttps://www.medtronic.com
Lenehan was a financial consultant since 2004, including serving as Senior Advisor of Cerberus Operations and Advisory Company, LLC, a private investment firm. Within the past five years, Mr. Lenehan served as a director of Talecris Biotherapeutics Holding Corporation a global biopharmaceutical company.

Medtronic PLC Management Efficiency

The company has Return on Asset of 0.0442 % which means that on every $100 spent on assets, it made $0.0442 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0795 %, implying that it generated $0.0795 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.11 in 2024, whereas Return On Capital Employed is likely to drop 0.05 in 2024. Total Current Liabilities is likely to gain to about 11.3 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 94.5 B in 2024
Medtronic PLC has 26.05 B in debt with debt to equity (D/E) ratio of 0.51, which is OK given its current industry classification. Medtronic PLC has a current ratio of 1.72, which is typical for the industry and considered as normal. Note however, debt could still be an excellent tool for Medtronic to invest in growth at high rates of return.

Similar Executives

Showing other executives

DIRECTOR Age

Arthur HigginsZimmer Biomet Holdings
65
Paul LaVioletteEdwards Lifesciences Corp
63
Nancy McKinstryAbbott Laboratories
62
Phebe NovakovicAbbott Laboratories
62
Roch DoliveuxStryker
64
Betsy BernardZimmer Biomet Holdings
65
Christopher BegleyZimmer Biomet Holdings
68
Mary BrainerdStryker
67
Sally BlountAbbott Laboratories
59
Stephen MacMillanBoston Scientific Corp
56
Charles DockendorffBoston Scientific Corp
66
Nelda ConnorsBoston Scientific Corp
55
Edward LiddyAbbott Laboratories
74
William OsbornAbbott Laboratories
73
Patricia GonzalezAbbott Laboratories
49
Daniel StarksAbbott Laboratories
66
Ellen ZaneBoston Scientific Corp
69
Andrew SilvernailStryker
50
Glenn TiltonAbbott Laboratories
72
John StrattonAbbott Laboratories
60
Leslie HeiszEdwards Lifesciences Corp
60
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 95000 people. Medtronic PLC (MDT) is traded on New York Stock Exchange in USA. It is located in Building Two, Galway, Ireland and employs 95,000 people. Medtronic PLC is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Medtronic PLC Leadership Team

Elected by the shareholders, the Medtronic PLC's board of directors comprises two types of representatives: Medtronic PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medtronic. The board's role is to monitor Medtronic PLC's management team and ensure that shareholders' interests are well served. Medtronic PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medtronic PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Brett Wall, Executive Vice President and President Restorative Therapies Group
Jennifer Kirk, Chief Accounting Officer, Global Controller
Bradley Lerman, Senior Vice President General Counsel, Corporate secretary
Scott Cundy, Senior Officer
Scott Donnelly, Lead Independent Director
Kenneth Washington, Senior Officer
Richard Anderson, Lead Independent Director
Ryan Weispfenning, Vice President - Investor Relations
Mark Ploof, Senior Services
Sean Lennon, Chief Officer
Hooman Hakami, Executive Vice President and Group President of the Medtronic Diabetes Group
Elizabeth Nabel, Independent Director
Richard Kuntz, Senior Vice President and Chief Scientific, Clinical and Regulatory Officer
James Lenehan, Independent Director
Mei Jiang, Senior Innovation
John Liddicoat, Executive Vice President and President Americas Region
Robert White, Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group
Kevin Lofton, Independent Director
Craig Arnold, Independent Director
Kendall Powell, Lead Independent Director
Olaf Hedrich, Chief Officer
Sally Saba, Chief Inclusion and Diversity Officer
Denise OLeary, Independent Director
Omar Ishrak, Chairman of the Board, Chief Executive Officer
Brad Lerman, Senior Vice President General Counsel, Corporate secretary
Matt Walter, Chief Officer
Frank Chan, President Monitoring
Joon Hurh, VP Pacific
Torod Neptune, Senior Officer
Ivan Fong, General VP
Sean Salmon, Executive Vice President and President, Diabetes Operating Unit, President, Cardiovascular Portfolio
Gary Corona, Senior CFO
Carol Surface, Chief Human Resource Officer, Senior Vice President
Karen Parkhill, Chief Financial Officer, Executive Vice President
Que Dallara, Executive Unit
Gregory Smith, Executive Chain
Michael Leavitt, Independent Director
Geoffrey Martha, Executive Vice President and President - Restorative Therapies Group
Robert Hopkins, Senior Strategy
Randall Hogan, Independent Director
Andrea Goldsmith, Independent Director
Robert Hoedt, Executive Vice President and President - EMEA Region
MSc MD, Medical Scientific
Michael Coyle, Executive Vice President, Group President - Cardiac and Vascular Group
MPH MD, Chief Business

Medtronic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medtronic PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Medtronic Stock Analysis

When running Medtronic PLC's price analysis, check to measure Medtronic PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medtronic PLC is operating at the current time. Most of Medtronic PLC's value examination focuses on studying past and present price action to predict the probability of Medtronic PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medtronic PLC's price. Additionally, you may evaluate how the addition of Medtronic PLC to your portfolios can decrease your overall portfolio volatility.